blank

Pedro Correa de Sampaio

In this insightful conversation recorded during Hello Tomorrow’s Global Summit in Paris, Pedro shares the vision behind Neobe Therapeutics, the challenges faced in developing their innovative solutions, and their progress towards revolutionizing cancer therapy.

Highlights

1. The Genesis of Neobe Therapeutics

Pedro co-founded Neobe Therapeutics with the aim of addressing a significant issue in the pharmaceutical industry: drug resistance in cancer treatment. Approximately 20% of cancer patients don’t respond to immunotherapies, which are drugs that activate an immune response against cancer. And that is the problem Pedro & his team are trying to solve – making these drugs work in more patients by breaking down their extracellular matrix. Neobe Therapeutics’ groundbreaking approach involves using engineered bacteria to overcome drug resistance, offering hope for more effective treatment options.

2. Harnessing the Power of Engineered Bacteria

Neobe Therapeutics designs bacteria that specifically target tumors, bypassing healthy tissues. By programming these bacteria to produce enzymes that can break down the extracellular matrix of drug-resistant tumors, they enable the cancer drugs to penetrate and effectively treat the tumors.

3. Neobe’s Unique Approach to Funding

Pedro explains that Neobe Therapeutics’ approach to funding is quite different from traditional biotech startups. The company’s strategy involved securing early-stage funding through organizations like Deep Science Ventures, which offers both financial support and mentorship. This approach allows Neobe to maintain control over their intellectual property and equity, providing them with more flexibility in their research and development process.

4. Progress and Future Plans

Neobe Therapeutics has two products in its pipeline, targeting specific subtypes of colon and breast cancer. The company is currently raising funds to conduct pre-clinical work, with the aim of entering first-in-human trials by 2025 or 2026.

5. Educating and Engaging the Community

Pedro acknowledges the importance of educating the public, the medical community, and regulators about the safety and efficacy of using engineered bacteria in cancer treatment. Neobe Therapeutics is committed to working closely with all stakeholders to ensure their approach gains acceptance and becomes a viable option for cancer patients.

Neobe Therapeutics is paving the way for a new era in cancer treatment by harnessing the power of engineered bacteria. With a unique approach to funding, a focus on education and engagement, and a dedicated team working tirelessly to develop innovative solutions, the company holds great promise in the fight against drug-resistant cancers. As Neobe continues its journey towards bringing these groundbreaking therapies to market, we eagerly anticipate the positive impact they will have on the lives of countless cancer patients.

Find Pedro on:

Find Ben on:

you might also like

Blog
blank

In April 2024, Voyage Foods, a Foodtech startup founded in 2021, partnered with Cargill, a global leader in food ingredients. This collaboration focuses on scaling innovative alternatives to cocoa-based chocolate and nut spreads. It addresses the growing demand for sustainable, allergen-free, and plant-based foods. The partnership shows how startups can work with established corporations to expand their reach and impact in the market. What is Voyage Foods? Reimagining traditional ingredients Founded in 2021, Voyage Foods develops alternatives to traditional food products using cutting-edge technology. Their innovations replicate the flavors and textures of familiar foods while addressing critical challenges such as sustainability and allergen concerns. Key products include: These products are free from the top nine allergens, vegan, and significantly more sustainable. For example, their cocoa-free chocolate reduces greenhouse gas emissions by up to 84% and uses 99% less water compared to conventional chocolate. Who is Cargill? Leveraging global expertise in food ingredients Cargill, with over a century of experience, is a global leader in food ingredients, supplying chocolate, coatings, starches, sweeteners, and oils to manufacturers worldwide. The company specializes in helping manufacturers bring high-quality products to market by offering a robust distribution network and industry expertise. By partnering with Voyage Foods, Cargill has expanded its portfolio to include cocoa-free chocolate and nut-free spreads. This addition helps manufacturers meet consumer demand for allergen-friendly and sustainable options. With its ability to connect startups like Voyage Foods to a global audience, Cargill plays a critical role in enabling innovation to scale. How the partnership works The collaboration allows Voyage Foods to focus on product development while benefiting from Cargill’s resources and infrastructure. Through this partnership: This partnership has also strengthened investor confidence in Voyage Foods, as seen in the $52 million Series A+ funding the startup raised shortly after the deal was announced. Showcase at Food Ingredients 2024 At Food Ingredients Europe 2024, Cargill showcased their new product line in collaboration with Voyage Foods “Cargill Indulgence Redefined™”. They won the Future Foodtech Innovation Award. The product line included indulgent chocolate-free confections filled with hazelnut and peanut flavors that we were able to taste. Additionally, cookies made with Voyage Foods’ cocoa-free chocolate chips were featured : Conclusion: A practical model for startup-corporate partnerships The partnership between Voyage Foods and Cargill is an example of how startups can collaborate with larger companies to achieve rapid growth. By combining innovation with the resources and scale of an established player, Voyage Foods has been able to bring its allergen-free and sustainable products to a global audience. For startups and founders in other industries, this case demonstrates that strategic partnerships can be a powerful way to solve challenges, expand markets, and drive long-term success.

Blog
AI Entrepreneurship Events Finland
Taito.ai Kristo Ovaska interviewed on the Builder Stage at Slush 2024 on his first 365 days as a founder

“Taito.ai’s whose name translates to “skill” in Finnish, positions itself as a scalable, AI-powered solution that enables continuous feedback and coaching on employee performance.

AI + 3
Podcast
blank

In this episode, Sirli Rosenvald shares her insights into the evolving field of alternative proteins, highlighting innovations in mycoproteins, challenges in scaling production, and the role of global markets in shaping FoodTech.

Podcast

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.